期刊
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, VOL 56
卷 56, 期 -, 页码 85-102出版社
ANNUAL REVIEWS
DOI: 10.1146/annurev-pharmtox-010715-103111
关键词
ABCB1; P-glycoprotein; chemotherapy; platinum compounds; multidrug resistance
资金
- NATIONAL CANCER INSTITUTE [ZIABC010830] Funding Source: NIH RePORTER
- Intramural NIH HHS Funding Source: Medline
Resistance to anticancer drugs is a complex process that results from alterations in drug targets; development of alternative pathways for growth activation; changes in cellular pharmacology, including increased drug efflux; regulatory changes that alter differentiation pathways or pathways for response to environmental adversity; and/or changes in the local physiology of the cancer, such as blood supply, tissue hydrodynamics, behavior of neighboring cells, and immune system response. All of these specific mechanisms are facilitated by the intrinsic hallmarks of cancer, such as tumor cell heterogeneity, redundancy of growth-promoting pathways, increased mutation rate and/or epigenetic alterations, and the dynamic variation of tumor behavior in time and space. Understanding the relative contribution of each of these factors is further complicated by the lack of adequate in vitro models that mimic clinical cancers. Several strategies to use current knowledge of drug resistance to improve treatment of cancer are suggested.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据